Ireland· IE-PA-EU/1/16/1167/002
Truxima 100 mg concentrate for solution for infusion
A rituximab product, registered in Ireland by Celltrion Healthcare Hungary Kft.. The same ATC class is registered in 3 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Rituximab is registered in 3 of 19 countries.
Countries holding a registration under ATC L01XC02 (rituximab), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 2 of them publish a price we can compare per daily dose
Rituximab · ATC L01XC02
3 / 19 countries
- Belgiumprice
- Ireland
- Polandprice
The record
At a glance
HPRA (Ireland)- Manufacturer
- Celltrion Healthcare Hungary Kft.
- Country
- Ireland (IE)
- ATC code
- L01XC02
- ATC class
- Rituximab
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/16/1167/002
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
81 interactions on record for rituximab.
Graded by severity as the source publishes them — 32 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Rituximab · interactions on record
81 records
- 32 severe
- 42 moderate
- 7 minor
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L01XC02
Rituximab, as other registers publish it.
- IrelandBlitzima 100 mg concentrate for solution for infusionCelltrion Healthcare Hungary Kft.
- PolandItuxrediReddy Holding GmbH
- PolandItuxrediReddy Holding GmbH
- IrelandMabThera 100 mg concentrate for solution for infusionRoche Registration GmbH
- IrelandMabThera 1400 mg concentrate for solution for infusionRoche Registration GmbH
- IrelandMabThera 1600 mg concentrate for solution for infusionRoche Registration GmbH
- IrelandMabThera 500 mg concentrate for solution for infusionRoche Registration GmbH
- BelgiumRitemvia 100 mgCelltrion Healthcare Hungary
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e95a96e9-28ef-46f2-986a-4349f61696b7 GET /v1/drugs/e95a96e9-28ef-46f2-986a-4349f61696b7?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Concentrate for solution for infusion",
"routes": [
"Intravenous use"
],
"source": "hpra",
"atc_all": [
"L01XC",
"L01XC02"
],
"strength": null,
"pa_number": "EU/1/16/1167/002",
"substances": null,
"legal_basis": "Similar biological application (Article 10(4) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": null,
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about rituximab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.